● Naïve human phage display library(1.5×1010)
● Synthetic humanised llama VHH library(2×1012)
● Immunized llama VHH library(107~ 108)
● Hybridomas ● Humanisation and affinity maturation ● Fc engineering and thermal stability optimization ● Bispecific antibody engineering platform● First biosimilar approved and launched in China - 汉利康® (rituximab)
● First Chinese mAb biosimilar launched in both the EU and China - 汉曲优® (Zercepac® in the EU, trastuzumab)
● The Company’s first product indicated for autoimmune diseases - 汉达远® (adalimumab)
● NDAs of serplulimab (anti-PD-1 mAb) - MSI-H, HLX04 (bevacizumab) and HLX01 (rituximab) - RA accepted by the NMPA for review